Table 5. Baseline characteristics of patients with SII ≤324.55×109 versus SII >324.55×109 in the training and validation cohorts.
| Baseline characteristics | Training cohort | Validation cohort | |||||
|---|---|---|---|---|---|---|---|
| SII <324.55 (n=101) | SII >324.55 (n=155) | P | SII <324.55 (n=63) | SII >324.55 (n=84) | P | ||
| Age (≤50 years) | 17 | 36 | 0.283 | 21 | 25 | 0.778 | |
| Gender (male) | 22 | 27 | 0.787 | 9 | 17 | 0.473 | |
| HBV (yes) | 80 | 127 | 0.704 | 52 | 70 | 1.000 | |
| Tumor size (≤3 cm) | 68 | 79 | 0.014 | 49 | 45 | 0.004 | |
| Tumor number (single) | 68 | 79 | 0.014 | 42 | 31 | <0.001 | |
| Cirrhosis (yes) | 90 | 143 | 0.524 | 58 | 76 | 0.967 | |
| CTP (A) | 100 | 152 | 0.935 | 63 | 83 | 1.000 | |
| MELD (≤4.81) | 52 | 84 | 0.077 | 28 | 40 | 0.830 | |
| ALBI grade | 0.834 | 0.643 | |||||
| 1 | 54 | 77 | NA | 30 | 42 | NA | |
| 2 | 45 | 75 | NA | 33 | 41 | NA | |
| 3 | 2 | 3 | NA | 0 | 1 | NA | |
| AFP (≤20 ng/mL) | 78 | 70 | <0.001 | 58 | 25 | <0.001 | |
| ALT (≤40 U/L) | 76 | 115 | 0.966 | 50 | 63 | 0.672 | |
| AST (≤40 U/L) | 82 | 133 | 0.418 | 56 | 67 | 0.209 | |
| γ-GT (≤60 U/L) | 73 | 94 | 0.076 | 40 | 53 | 1.000 | |
| TBIL (≤17.1 μmol/L) | 63 | 96 | 1.000 | 60 | 77 | 0.603 | |
| ALB (≤43.2 g/L) | 84 | 128 | 1.000 | 48 | 67 | 0.751 | |
| Tumor recurrence (yes) | 17 | 92 | <0.001 | 12 | 62 | <0.001 | |
HBV, hepatitis B virus; AFP, alpha-fetoprotein; CTP, Child-Turcotte-Pugh; MELD, Model for End-Stage Liver Disease; ALB, albumin; ALT, alanine aminotransferase; AST, aspartic transaminase; γ-GT, γ-glutamyl transpeptidase; TBIL, total bilirubin.